The use of procalcitonin in patients of acute exacerbation of chronic obstructive disease in which people within intervention group will not receive antibiotic and will be seen for progression to severe disease, time to clinical resolution and days of antibiotic exposure in control group.
Phase 3
- Conditions
- Health Condition 1: J441- Chronic obstructive pulmonary disease with (acute) exacerbation
- Registration Number
- CTRI/2024/05/068078
- Lead Sponsor
- Bharti
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Patient should be a diagnosed case of COPD.
2) Patient should have moderate acute exacerbation of COPD according to latest GOLD guidelines 2023.
3) On presentation procalcitonin levels should be less than 0.1 mcg per liter.
Exclusion Criteria
1) Mild and severe cases of acute exacerbation of COPD.
2) Those with lobar consolidation patch on chest X ray.
3) Received antibiotic for more than 48 hours at time of enrollment.
4) Immunocompromised patients, i.e. HIV infection, neutropenic patients (1000 × 109 per L), stem cell transplant recipients, patients of leukemia/lymphoma.
5) Co-existence of inflammatory conditions which can lead to increase in serum PCT levels
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method